ABA3 GVHD ProRx post Allo HACT

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking the study drug, abatacept, by intravenous (IV) infusion. Along with the study drug, participants will take a either cyclosporine or tacrolimus, and methotrexate, which are standard medications for transplant patients. Participants, 6 years of age and older, will be randomized (placed into a group by chance) by the study team. After being placed into a group, you will receive additional doses of either abatacept (the study drug) or a placebo (an inactive substance).

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at hartmanj2 [at] chop.edu or 215-590-1936.

Eligibility & Criteria

IRB #:
22-020588
Official Title:
A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Study Phase:
Phase II
Eligible Age Range:
2 - 99 Years
Gender:
All
Study Categories:

Visit Criteria

If you agree to take part, your participation will last for about 2 years post-transplant. You will receive study treatment for 150 days post-transplant. There are differences between this study and your usual care. As a participant in the research, you will be given abatacept (or placebo) by IV infusion. Study visits will include the following assessments: blood draws, pregnancy testing/birth control, genetic testing, and tissue collections (for clinical and research purposes). Some of these assessments are only if you are 18 years or older. All participation will occur at CHOP's main campus in Philadelphia.

Leader
Alix E. Seif

Alix E. Seif, MD, MPH